Community-acquired pneumonia in children is common in China. To understand current clinical characteristics and practice, we conducted a cross-sectional study to analyze quality of care on childhood pneumonia in eight eastern cities in China.
28 April 2010 in The Kaohsiung Journal of Medical Sciences
High-performance liquid chromatography coupled with an ultraviolet detector was used to quantitatively determine the amount of caffeoylquinic acid, arctium lappa glycoside, aurantiamarin and forsythin present in five solvent extracts (water, 30% ethanol, 50% ethanol, 70% ethanol and 95% ethanol) of Yinqiaosan (YQS). The calibration curves of the four components were linear (r(2) > 0.998) over the concentration range of 0.9-151.5 microg/mL. This method showed good repeatability with relative standard deviations of less than 2.9% and mean recoveries of 91.3-100.5%. We established the relative amounts of each of the four main ingredients in YQS for all five solvent extracts. The direct inhibitory effects of the five YQS extracts on influenza-A virus in vitro and the therapeutic effects on infected embryonated hen eggs were evaluated. YQS extracted in 50% ethanol and used at concentrations of 500 mg/mL and 250 mg/mL exerted the greatest therapeutic effect in infected embryonated hen eggs and was significantly superior to ribavirin (p < 0.05). Therefore, the 50% ethanol extract of YQS seems to be the most effective for the inhibition of influenza-A virus. Based on these results, further studies are warranted to evaluate the use of YQS extracts as a possible therapy for influenza.
Background Respiratory syncytial virus (RSV) pneumonia is a major cause of hospitalization in children worldwide, seriously endangering child health. In recent years, many clinical studies have shown that traditional Chinese medicine (TCM) has unique advantages in the treatment of pediatric viral pneumonia. Therefore, it is particularly important to strengthen exploration of and research into the use of TCM to treat RSV pneumonia in children. The aims of this study will be to evaluate the clinical effect of Xiaoer Dingchuan Granule (XDG) on RSV pneumonia and to provide a scientific basis for clinical diagnosis and treatment. Methods and Design: This study will be a single-blinded, parallel-controlled, multicenter randomized clinical trial (RCT) conducted in 10 Class III Grade A hospitals nationwide. We will recruit the study population from children aged 1–5 years who have been diagnosed with RSV pneumonia by Western medicine and with pneumonia and cough by TCM (phlegm-heat blocking lung syndrome) with a disease course within 48 h. The children’s parents or guardians will sign their informed consent. A total of 240 children will be recruited and divided into an experimental group and a control group. The control group will receive basic treatment, and the experimental group will receive XDG. Children will be treated for 7 days, and changes in their conditions will be evaluated daily and input to the medical-record observation form. We will follow-up on them at 10 and 90 days after discharge to observe their prognosis. After data collection, we will comprehensively evaluate the clinical efficacy of pediatric XDG as intervention into syncytial-virus pneumonia by its total effective rate, the curative-effect time window of pediatric pneumonia, the curative effect of TCM syndrome, changes in individual symptoms, changes in pulmonary signs, and the use of drug combinations. Discussion We speculate that treatment of RSV pneumonia in children with TCM can increase the overall clinical efficiency, alleviate disease severity, shorten hospital stays, reduce pain, and improve the children’s quality of life. Trial Registration: Chinese Clinical Trial Registry No. ChiCTR2200061471